Anne McGeorge
CIK 1779934 · last filed 2026-08-11
Anne McGeorge is a corporate insider who has filed 20 SEC Form 4 insider transactions across 5 companies since 2019. The most recent filing, for DNTH, was dated Aug 11, 2026. Across all open-market trades the lifetime net is −$844.8K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $558.7K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
DNTH price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
100 TECHNOLOGY SQUARE, 5TH FLOOR
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DNTH | Director | 7,750 | $72.09 | $558.7K | -$844.8K | 5 | 2026-08-11 |
| Oncology Institute, Inc. (TOI) Delisted | Director | 332,535 | $5.13 | $1.71M | $0 | 2 | 2026-07-29 |
| Oncology Institute, Inc. (TOIIW) Delisted | Director | 291,370 | $0.05 | $14.3K | $0 | 5 | 2025-11-24 |
| Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Director | — | $11.19 | — | $0 | 4 | 2022-06-30 |
| SOC Telemed, Inc. (TLMDW) Delisted | Director | 0 | $0.84 | $0 | $0 | 3 | 2022-04-07 |
Recent Filings
20 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-11 | DNTH | Mixed | — | -$747.8K | EDGAR |
| 2026-08-10 | DNTH | Notice (144) | −7,750 | -$844.1K | EDGAR |
| 2026-07-29 | Oncology Institute, Inc. (TOI) Delisted | Grant (A) | +41,165 | $0 | EDGAR |
| 2026-05-22 | DNTH | Grant (A) | — | $0 | EDGAR |
| 2025-11-24 | Oncology Institute, Inc. (TOIIW) Delisted | Grant (A) | +108,024 | $0 | EDGAR |
| 2025-05-22 | DNTH | Grant (A) | — | $0 | EDGAR |
| 2024-11-25 | Oncology Institute, Inc. (TOIIW) Delisted | Grant (A) | +56,000 | $0 | EDGAR |
| 2024-05-28 | DNTH | Grant (A) | — | $0 | EDGAR |
| 2023-12-28 | Oncology Institute, Inc. (TOIIW) Delisted | Grant (A) | +56,000 | $0 | EDGAR |
| 2023-09-13 | DNTH | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.